SLI15 Antibody

What is SLI15 and why is it significant in cell biology research?

SLI15 is an essential protein in budding yeast (Saccharomyces cerevisiae) that forms part of the chromosomal passenger complex. It associates with the Ipl1 protein kinase to promote proper chromosome segregation . SLI15 is the yeast homolog of INCENP (Inner Centromere Protein) in higher eukaryotes, making it an important model for understanding conserved mitotic mechanisms. Its significance stems from its critical role in linking centromeres to spindle microtubules and ensuring accurate segregation of the genome during cell division . Research has shown that SLI15, in complex with Bir1 (the yeast homolog of Survivin), connects centromeres to microtubules, which is essential for proper chromosome alignment and segregation .

What are the key structural domains of SLI15 relevant to antibody development?

SLI15 contains several functional domains that should be considered when developing or selecting antibodies:

• PR region (residues ~2-450): Part of the microtubule-binding domain that is essential for viability

• Centromere (CEN) box: Another region involved in localization

• SAH (Single Alpha Helix): A putative structural element important for function

• IN box domain: Located at the C-terminus, binds to and activates Ipl1 kinase

When developing antibodies against SLI15, targeting conserved regions like the IN box may provide cross-reactivity across species, while antibodies against more variable regions might offer species specificity. The W646 and F680 residues in the IN box are particularly conserved and critical for binding to Ipl1 kinase .

How can researchers effectively use SLI15 antibodies for immunoprecipitation studies?

For successful immunoprecipitation of SLI15:

• Epitope selection matters: Antibodies targeting the C-terminus have been successfully used in previous studies, as demonstrated in work where anti-Sli15 antibodies were raised against the C-terminus .

• Co-immunoprecipitation strategy: When studying SLI15's interaction partners, consider that:

  • SLI15 forms a complex with Bir1, but this complex may not include Ipl1 in all conditions

  • The Bir1-Sli15 complex can be purified using tandem affinity purification (TAP) techniques

• Cross-linking protocol:

  • For transient interactions, implement a mild cross-linking step using 0.1-0.5% formaldehyde

  • Use gentle lysis conditions to preserve protein complexes (avoid strong detergents)

• Controls to include:

  • Input sample (pre-immunoprecipitation)

  • Non-specific IgG control

  • Immunoprecipitation from strains expressing tagged versions of SLI15 (e.g., HA-tagged or TAP-tagged SLI15)

What are the optimal conditions for immunofluorescence microscopy using SLI15 antibodies?

Based on research protocols for visualizing SLI15 localization:

• Fixation protocol:

  • Formaldehyde fixation (3.7%) for 10-15 minutes at room temperature

  • For improved spindle visualization, methanol/acetone fixation may provide better results

• Cell permeabilization:

  • 0.1% Triton X-100 in PBS for 10 minutes

• Antibody dilution range:

  • Primary antibody: 1:500 to 1:2000 depending on antibody quality

  • Include a pre-adsorption step against fixed cells lacking SLI15 to reduce background

• Expected localization patterns:

  • Preanaphase: SLI15 associates with the spindle, with intensity varying based on cell cycle stage

  • Anaphase: Strong spindle midzone localization

  • Different mutants show distinct localization patterns; for example, GST-Sli15Δ2-450 and GST-Sli15Δ2-500 show preanaphase spindle fluorescence similar to wild-type SLI15

How can SLI15 antibodies be used to distinguish between different functional complexes of SLI15?

SLI15 exists in different functional complexes that can be distinguished using carefully designed immunoprecipitation experiments:

• Bir1-Sli15 complex vs. Ipl1-Sli15 complex:

  • Research has shown that a complex containing Bir1 and Sli15 can function in connecting centromeres to microtubules without Ipl1

  • Sequential immunoprecipitation using antibodies against different complex members can separate these distinct complexes

• Experimental approach to complex separation:

  Experimental Step	Bir1-Sli15 Complex	Ipl1-Sli15 Complex
  First IP Antibody	Anti-Bir1	Anti-Ipl1
  Secondary IP	Anti-Sli15	Anti-Sli15
  Expected Result	Bir1-Sli15 without Ipl1	Ipl1-Sli15
  Functional Assay	CEN DNA-microtubule binding	Kinase activity assay

• Analytical strategy:

  • Immunoblotting of fractionated complexes can reveal distinct distributions

  • Mass spectrometry analysis of TAP-purified complexes has previously identified Sli15 in complex with Bir1 but not Ipl1

  • Activity assays can differentiate complexes: Bir1-Sli15 mediates microtubule binding, while Ipl1-Sli15 provides kinase activity

What experimental approaches should be used to study the effect of SLI15 mutants on chromosome segregation?

Based on published methodologies:

• Mutant generation strategies:

  • In vitro error-prone PCR and in vivo gapped-repair can be used for mutagenesis of SLI15

  • Sequential deletion constructs targeting specific regions (e.g., PR region, IN box) have been created to study domain functions

  • Point mutations in critical residues (e.g., W646G and F680A in the IN box) can disrupt specific interactions

• Phenotypic analysis methods:

  • Tetrad dissection to assess viability of mutant spores

  • Growth assays on rich media and benomyl-containing media to assess microtubule-related defects

  • Direct measurement of chromosome missegregation rates using colony sectoring assays or fluorescent markers

• Suppressor screening:

  • Artificial dimerization using GST fusion has been shown to suppress the biorientation defect and lethality associated with deletions in the Sli15 microtubule-binding domain

  • Inducible heterodimerization systems (e.g., FKBP-FRB with rapamycin) can be used to test rescue hypotheses

How can researchers validate the specificity of SLI15 antibodies?

Validation strategies should include:

• Genetic controls:

  • Test antibody reactivity against extracts from wild-type cells versus SLI15-depleted cells (e.g., using pGAL-SLI15 strains grown in glucose)

  • Use strains with different tagged versions of SLI15 to confirm the antibody recognizes the correct protein

• Biochemical validation:

  • Immunoblotting should show bands of the expected molecular weight

  • The presence of full-length and truncated versions of SLI15 can be detected and differentiated by immunoblotting with antibodies raised against the C-terminus of Sli15

  • Immunodepletion experiments: >90% depletion of HA-tagged Sli15 should dramatically reduce activity in functional assays

• Signal specificity tests:

  • Pre-adsorption of antibody with purified antigen should eliminate specific signal

  • For immunofluorescence, signal should match known localization patterns and change appropriately during the cell cycle

What are common pitfalls in SLI15 antibody experiments and how can they be addressed?

• Cross-reactivity issues:

  • SLI15 antibodies may cross-react with other coiled-coil proteins

  • Solution: Validate against SLI15-depleted extracts and use pre-adsorption techniques

• Low signal in immunoprecipitation:

  • The Bir1-Sli15 complex may be present at low abundance

  • Solution: Increase starting material or use TAP-tagging approach for better enrichment

• Misinterpretation of mutant phenotypes:

  • Some SLI15 mutants maintain partial function

  • Example: sli15-3 mutant encodes a protein that's defective in Ipl1 activation but still capable of linking CEN DNA to microtubules in vitro

  • Solution: Use multiple functional assays and genetic backgrounds

• Altered expression levels affecting results:

  • Overexpression or depletion can mask or exaggerate phenotypes

  • Solution: Monitor protein levels by immunoblotting and use controlled expression systems like pGAL-SLI15

How should researchers interpret discrepancies between in vitro and in vivo results with SLI15 antibodies?

When faced with discrepancies:

• Consider complex formation differences:

  • In vitro experiments may not recapitulate the full complement of interaction partners

  • Example: Purified Bir1-Sli15 complex had no activity on its own, but exhibited robust activity when mixed with (PP)CBF3

• Evaluate expression levels:

  • Artificial systems may result in different protein concentrations than endogenous conditions

  • Immunoblotting should be used to compare protein levels between experimental systems

• Account for post-translational modifications:

  • Phosphorylation status of SLI15 affects its localization and function

  • In vitro systems may lack proper kinases or phosphatases

• Analyze domain-specific functions:

  • Different assays may preferentially detect certain functions of SLI15

  • For example, in vivo spindle localization versus in vitro microtubule binding may be mediated by different domains

What quantitative methods are most appropriate for analyzing SLI15 antibody-based experiments?

• Immunofluorescence intensity quantification:

  • Use line scans across structures of interest (spindles, kinetochores)

  • Normalize to a stable reference (tubulin signal for spindles)

  • Compare relative intensities between wild-type and mutant cells under identical acquisition settings

• Co-localization analysis:

  • Calculate Pearson's correlation coefficient between SLI15 and partner proteins

  • Use distance measurements for centromere-microtubule attachment analysis

• Kinase activity quantification:

  • Measure substrate phosphorylation levels by immunoblotting with phospho-specific antibodies

  • Normalize to total protein levels to account for expression differences

• Microtubule binding assay quantification:

  • Calculate the percentage of CEN DNA associated with microtubules in various extracts

  • Compare activities between different mutant extracts and conditions

How might new antibody technologies advance SLI15 research?

Emerging antibody technologies offer new opportunities:

• Single-domain antibodies (nanobodies):

  • Smaller size allows better penetration into complex structures

  • Can be expressed intracellularly to track SLI15 in living cells

• Proximity-labeling antibodies:

  • Antibodies conjugated to enzymes like BioID or APEX

  • Can map the local interactome of SLI15 at different cell cycle stages

• Bi-specific antibodies:

  • Could be designed to detect specific SLI15 complexes by simultaneously binding two proteins

  • Might distinguish Bir1-Sli15 from Ipl1-Sli15 complexes in situ

• Conditional degradation systems combined with antibody detection:

  • Rapid depletion of SLI15 followed by time-course analysis with antibodies

  • Would reveal immediate versus adaptive consequences of SLI15 loss

What are the most promising research questions about SLI15 that antibodies could help address?

Key questions include:

• Temporal dynamics of SLI15 interactions:

  • When and where do different SLI15 complexes form and dissociate?

  • How does phosphorylation regulate these dynamics?

• Stoichiometry questions:

  • What is the oligomeric state of SLI15 in different complexes?

  • Does clustering on microtubules create higher-order structures?

• Structure-function relationships:

  • How does the putative SAH domain contribute to SLI15 function?

  • What conformational changes occur upon binding to different partners?

• Evolutionary conservation:

  • How conserved are SLI15 functions between yeast and higher eukaryotes?

  • Could findings translate to cancer research through INCENP studies?